[Controlled-release oxycodone--a therapeutic option for severe neuropathic pain. Two multicenter observational...

Area of Science:

• Pharmacology and Pain Management
• Neurology
• Clinical Research

Background:

• Neuropathic pain is a debilitating condition affecting quality of life.
• Controlled-release oxycodone is a prescribed opioid analgesic for pain management.
• Postmarketing surveillance is crucial for evaluating real-world drug effectiveness and safety.

Purpose of the Study:

• To evaluate the efficacy of controlled-release oxycodone in patients with neuropathic pain.
• To assess the impact of treatment on pain intensity and functional impairment.
• To determine changes in quality of life and daily performance during treatment.

Main Methods:

• Two postmarketing studies (PMS) included 603 patients with neuropathic pain.
• Patients received controlled-release oxycodone.
• Pain intensity and functional impairment were measured using a numeric rating scale (NRS) at baseline, 1 week, and 3 weeks.

Main Results:

• Mean pain intensity decreased from over 6 at baseline to approximately 4 at 1 week and under 3 at 3 weeks.
• The average daily dose of oxycodone reached just over 40 mg by week 3.
• Significant improvements were observed in functional impairment, quality of life, daily activities, mood, sleep quality, and overall well-being.

Conclusions:

• Controlled-release oxycodone demonstrates significant efficacy in reducing pain intensity for neuropathic pain patients.
• The treatment leads to substantial improvements in functional capacity and overall quality of life.
• Postmarketing data support the effectiveness of controlled-release oxycodone in a real-world clinical setting.